Drug · CHEMBL495
ALPROSTADIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ALPROSTADIL. Drugs and targets, record CHEMBL495. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL495
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Caverject, Caverject impulse, Edex, Prostin vr, Prostin vr pediatric, Viridal 10, Viridal 20, Viridal 5, Viridal duo, Vitaros
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 19 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGER1 | Prostaglandin E2 receptor EP1 subtype | Prostanoid EP1 receptor agonist | AGONIST | https://conductscience.org/library/genes/5731 |
| PTGER2 | Prostaglandin E2 receptor EP2 subtype | Prostanoid EP2 receptor agonist | AGONIST | https://conductscience.org/library/genes/5732 |
Source ChEMBL
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| erectile dysfunction | Approval | ATC, DailyMed and TTD | 15 | 8 | https://conductscience.org/library/drugs?q=MONDO_0005362 |
| pulmonary hypertension | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
| diabetic foot | Approval | TTD | 2 | 1 | https://conductscience.org/library/drugs?q=EFO_1001459 |
| COVID-19 | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| Thromboembolism | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0001907 |
| acute respiratory distress syndrome | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006502 |
| adult acute respiratory distress syndrome | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0100130 |
| age-related macular degeneration | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005150 |
| arteriosclerosis obliterans | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006659 |
| diabetes mellitus | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005015 |
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials42
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00596752 | Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV | Phase 4 | 840 | 2014-08-12 | alprostadil | Its name | ClinicalTrials.gov |
| NCT01263925 | Prostaglandin E1 in Outpatients With Intermittent Claudication | Phase 3 | 561 | 2012-06-29 | prostaglandin e1 | Its name | ClinicalTrials.gov |
| NCT00544076 | ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer | Phase 3 | 110 | 2019-01-02 | alprostadil | Its name | ClinicalTrials.gov |
| NCT00955929 | Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy | 76 | 2021-11-08 | prostaglandin E1 | Its name | ClinicalTrials.gov | |
| NCT00619229 | Alprostadil in Maculopathy Study (AIMS) | Phase 3 | 37 | 2011-04-11 | alprostadil | Its name | ClinicalTrials.gov |
| NCT02628106 | Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy | Phase 4 | 21 | 2016-05-24 | lipo-prostaglandin E1 | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01467076 | Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF) | Phase 2 | 7 | 2016-12-30 | prostaglandin E1 | Its name | ClinicalTrials.gov |
| NCT03252626 | Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke | Phase 4 | 950 | alprostadil | Its name | ClinicalTrials.gov | |
| NCT02223949 | Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening Methods | Phase 2/3 | 624 | prostaglandin E1 | Its name | ClinicalTrials.gov | |
| NCT00610051 | ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure | Phase 3 | 600 | alprostadil | Its name | ClinicalTrials.gov |
1 to 10 of 42
See all 42 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alprostadil vs Placebo: All-cause Mortality During the Course of the Study (up to 196 Days) | 20 of 416 | 15 of 423 | 839 | NCT00596752 | Trial comparisons |
| Alprostadil vs Placebo: Cardiovascular Mortality During the Course of the Study (up to 196 Days) | 11 of 416 | 14 of 423 | 839 | NCT00596752 | Trial comparisons |
| Alprostadil vs Placebo: serious adverse events | 87 of 416 | 62 of 423 | 839 | NCT00596752 | Trial comparisons |
| Alprostadil vs Placebo: Minor Amputations at 24 Weeks After the End of Study Drug Treatment | 65 of 316 | 40 of 297 | 613 | NCT00596752 | Trial comparisons |
| Alprostadil vs Placebo: Revascularization Procedures at 24 Weeks After the End of Study Drug Treatment | 6 of 294 | 7 of 283 | 577 | NCT00596752 | Trial comparisons |
| Alprostadil vs Placebo: Complete Healing of Ischemic Necroses and Ulcerations at 24 Weeks After the End of Study Drug Treatment | 108 of 289 | 103 of 279 | 568 | NCT00596752 | Trial comparisons |
| Alprostadil vs Pentoxifylline: serious adverse events | 19 of 276 | 17 of 285 | 561 | NCT01263925 | Trial comparisons |
| Alprostadil vs Placebo: serious adverse events | 0 of 18 | 0 of 18 | 36 | NCT00619229 | Trial comparisons |
Papers from its trials10
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL495
GET https://conductscience.org/api/drugs/v1/CHEMBL495/trials?page=2